Visionary Holdings Stock Price, News & Analysis

Visionary Holdings Inc. (NASDAQ: GV) hosted a public welfare event in Hong Kong on March 8, 2025, focusing on women's health and cervical cancer screening. The company donated HK$230,000 worth of E7 protein detection kits to Sun Heart Care Charity Foundation.

The event highlighted Targeted Biotech USA's E7 protein home self-test kit, which has received FDA approval in China and the EU, with pending US FDA approval. The innovative technology offers:

• 15-minute rapid home screening for cervical cancer
• Increased detection accuracy from 10-30% to 80-90%
• Non-invasive, painless, and private testing solution

With an addressable market of approximately 2.5 billion women aged 15-65 worldwide, Targeted Biotech USA plans to launch 5 new home self-test products annually for various cancers and diseases.

Visionary (GV) has announced a major expansion into the new energy vehicle industry, developing an integrated ecosystem encompassing 'vehicle-station-power-cloud-research-finance'. The company plans strategic partnerships with Magna Group and Skyworth Group for vehicle manufacturing, targeting Hong Kong and Southeast Asian markets.

The ecosystem includes: battery swap stations network development with Chinese enterprises, battery lifecycle management system, intelligent cloud platform integration, and research collaborations with the University of Toronto. Financial services will be provided through partnership with OZTURK HOLDING, offering vehicle and battery leasing with low-interest loans.

The initiative focuses on standardized operations, real-time monitoring, and comprehensive market promotion through local media and social platforms. The ecosystem aims to create a complete closed-loop system integrating technology R&D, manufacturing, market promotion, and financial services.

Visionary Holdings has secured a significant order for 12,000 new energy vehicles specifically designed for the Hong Kong taxi market. The company plans to establish a comprehensive network of battery swap service stations across Hong Kong to support these vehicles.

The battery swap stations will feature advanced technology enabling quick battery replacement, offering faster energy replenishment compared to traditional charging methods. This system aims to minimize taxi downtime and maximize driver income. The service will be supported by an intelligent management system and mobile application for real-time monitoring of station locations and battery status.

This initiative represents a strategic expansion in the Hong Kong market and demonstrates Visionary's commitment to developing a comprehensive industrial ecosystem for new energy vehicles. The company aims to contribute to Hong Kong's green transportation goals while securing a significant position in the region's new energy vehicle market.

Visionary (GV) has secured a $1 billion financing consent letter from Qatar's Alfardan Group to support its PEGASUS new energy vehicles project. The funding will primarily be allocated to:

1. R&D investments focusing on core technical challenges including:

• Vehicle body structural strength
• Battery range enhancement
• Advanced 'three-electric' technologies
• Intelligent driving systems
• Solid-state batteries
• BMS systems development

2. Building advanced production facilities and implementing intelligent manufacturing equipment to prepare for large-scale commercial production.

3. Market expansion and brand building initiatives for the PEGASUS brand globally.

The company aims to establish a strong presence in European and American markets while pursuing global expansion through partnerships with international enterprises.

Visionary Holdings (NASDAQ: GV) has announced its entry into the new energy vehicle market with the launch of its PEGASUS brand in 2025. The company plans to introduce two initial models: a compact electric sedan with 400-500km range and a luxury SUV with 500-600km range.

The company will implement a cross-ocean collaborative model, with vehicle development and assembly in Canada while leveraging global automotive parts suppliers. The production plan targets 100,000 vehicles in the first year with expected revenue of $4 billion. By year five, Visionary projects $15 billion in revenue with net profits of $1.5-2 billion.

Key features include solid-state battery technology enabling 10-80% charging in 10 minutes, 85% automation rate in production, and a 40% local parts sourcing target. The company plans to establish direct sales experience stores globally and implement an integrated online-offline sales strategy.

Visionary Holdings (GV) has demonstrated significant achievements in implementing generative AI across FinTech and biotechnology sectors. The company's AI solutions have delivered notable improvements in their digital asset trading platform, including a 40% reduction in transaction delays and a 97.5% fraud detection rate.

In their FinTech operations, AI implementation has reduced labor costs by 40% while increasing customer satisfaction to 94.2%. Their biotechnology division has achieved a 98.7% sensitivity rate in AI-driven cervical cancer E7 protein detection, earning FDA certification.

The company's AI system operates on a four-layer architecture: Intelligent Perception, Cognitive Decision, Generative Execution, and Autonomous Evolution, enabling comprehensive solutions across financial and medical applications. According to IDC, AI is projected to contribute $19.9 trillion to the global economy by 2030, representing 3.5% of global GDP.

Visionary Holdings (NASDAQ: GV) has announced significant strategic expansion in the new-energy vehicle industry through a partnership with Pegasus International Holding The company plans to list its new-energy vehicle project on the NASDAQ Main Board within 6-12 months, with a subsequent plan to list Pegasus International on the Hong Kong Stock Exchange in 3-5 years.

Pegasus International has placed an order for 12,000 new-energy vehicles (Hong Kong taxi version) at HK$145,800 per unit. The company is expanding into Hong Kong and Southeast Asian markets, focusing on new-energy light-truck market and battery-swapping/charging services. This expansion leverages regional government incentives and growing market demand for electric vehicles.

The company has transformed from traditional education and real estate to establish a diversified multinational framework incorporating four core businesses: technology, education, finance, and real estate.

Visionary Holdings (NASDAQ: GV) has issued a comprehensive response to address capital market concerns and highlight its development trajectory. The company, focused on precision medicine and biomedical innovation, reports that its R&D expenditure maintains at 15% of total expenditure, primarily directed towards early cancer screening research.

The company's financial structure remains stable, supported by cash reserves, institutional credit, and strategic investments. Their key developments include home detection technologies for cervical and colorectal cancer, currently in clinical trials with expected market launch within 18 months. These tests offer 15-minute results and focus on detecting precancerous lesions at lower costs.

GV plans to implement a dual B2B and B2C commercialization strategy, partnering with healthcare facilities while offering direct-to-consumer sales through online channels. Future expansion will be funded through diverse financing channels, including strategic investment and bond financing, with careful consideration to minimize shareholder dilution.

Visionary Holdings (NASDAQ: GV) is advancing in the precision medicine field, particularly in targeted therapy development. The company has made strategic investments in developing third-generation EGFR inhibitors for non-small cell lung cancer and partnered with gene sequencing companies for liquid biopsy technologies.

The company is leveraging AI-assisted drug development and has established collaborations with global biotech leaders to develop next-generation anticancer drugs targeting specific gene mutations like HER2, BRAF, and KRAS. Their clinical trial network spans North America, Europe, and Asia. They've also developed rapid at-home testing technologies for cervical and colorectal cancers.

According to McKinsey Global Institute, the global biopharmaceutical market is projected to exceed $1.5 trillion by 2030, with precision medicine expected to grow at a CAGR of over 10%.